Control of vancomycin-resistant enterococci: it is important, it is possible, and it is cost-effective.
Mayhall
C Glen
CG
D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000191:economics / Q000517:prevention & control*; D016983:Enterococcus; D016908:Gram-Positive Bacterial Infections / Q000191:economics / Q000517:prevention & control*; D006801:Humans; D017053:Infection Control / Q000191:economics; D020713:Vancomycin Resistance